At StateoftheMarkets.com, we strive to “own the best and ignore the rest” in our equity portfolios. Toward this end, each day we search our database for a “top stock” (a top rated company in terms of earnings strength as well as company and industry performance) that presents a strong technical “set up” and a good entry point.
In short, when our equity team is looking to add a stock to one of our portfolios, the “bull’s eye” stock shown below is generally their first choice.
| Company | Symbol | Industry | Stock Rating | YTD% Gain | S.T. Stop Loss |
|---|---|---|---|---|---|
| Biogen Idec | BIIB | Biotechnology | 9.6 | +47.77% | $214.79 |
Why We Like The Stock:
Biogen Idec (BIIB) is our most compelling buy today due to the fact that it is a top rated stock (in terms of earnings strength and company/industry performance) with a positive technical set-up. Biotechnology has been a leader this year, as evidenced in charts like Gilead Sciences (GILD), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Biogen Idec, and even the SPDR Biotech ETF (XBI). BIIB has a stellar long-term uptrend dating all the way back to June of 2010, when it was priced just below $50. Now BIIB is still displaying technical strength, and good momentum moving forward. Recently, the stock hit late-May highs just north of $240, which would be the target of a short-term trade here. After pulling back in June, BIIB is back on the upswing, crossing above its short- and intermediate-term moving averages over the past couple of weeks. BIIB is a high flyer, but with such a pretty technical picture, is hard to pass up, even if only for a quick trade.
We Would Be Buyers:
At the current price (~$223.37).
Company Profile:
Biogen Idec Inc. is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN.
Stock Rating: 9.6
The Stock Rating indicates the combined score of our proprietary Earning Strength and Company Performance models. The rating scale is 0 – 10 with 10 being the highest.
Biogen Idec – Last Three Months
Biogen Idec – Last 12 Months
Biogen Idec – Last Five Years
At the time of publication the editor and affiliated companies own the following positions: None
Note: Positions may be bought or sold while this publication is in circulation without notice.
